The fact that OC and PPRF potently suppressed the expression of SMYD2, EZH2, and c-MET tyrosine 1349 and 1356 in collected primary tumors (Figure 9), validated their promotion to the lead rank, and proved the pharmacodynamic effects, as well as provided the pharmacological justification and evidence for their molecular targets in suppressing CRC progression, recurrences, and motility. The gene discussed is MET; the disease is colorectal carcinoma.